Clinical Trial Update: Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia [EARLY_Phase 1]

View source ↗

Summary

This early-phase (Phase 1) clinical trial evaluates the safety and potential efficacy of CI-135, a FLT3-targeted CAR-T cell therapy, for relapsed/refractory Acu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CI-135 (CI-135)

Snippet

Sponsor: Hrain Biotechnology Co., Ltd. | Conditions: Acute Myeloid Leukemia (AML) | EARLY_Phase 1 | Status: RECRUITING